HAE12, there are many facets to what SVFC is trying to do scientifically. Delays are the norm for start-up biotech companies attempting to get patent approvals, new processes accepted, etc.. Until they are able to generate enough revenue stay in business, money is, and always will be, the key factor to their ultimate success. Toxic financing is a killer unless a new deal is reached. You have to separate the toxic financing from everything else because of the agreement with YA. It isn't going away until a new agreement is reached to replace it and also one that satisfies YA. It doesn't matter how much progress the company is making on other fronts if financing is a mess. IMO, the company, as well as folks like Dr. Andrews are fully aware of this (that's why he is still involved), and progress is being made towards a new financial agreement.
SVFC$$$$
News 
Market Data 
Discover 
AI
